Skip to main content
Erschienen in: Critical Care 1/2020

Open Access 01.12.2020 | Research Letter

Early sepsis identification following cytoreductive surgery for peritoneal malignancy

verfasst von: Darius Cameron Wilson, Danylo Yershov, Chandrakumaran Kandiah, Nicholas Cortes, Kirsty Gordon, Kordo Saeed

Erschienen in: Critical Care | Ausgabe 1/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ANOVA
Analysis of variance
AUROC
Area under the receiver operating characteristic curve
CRP
C-reactive protein
CT-proET-1
C-terminal proendothelin-1
HIPEC
Hyperthermic chemoperfusion
MR-proADM
Mid-regional proadrenomedullin
PCT
Procalcitonin
SIRS
Systemic Inflammatory Response Syndrome
WCC
White cell count
Cytoreductive surgery for peritoneal malignancy often involves extensive tissue resection, a prolonged operating time, and a significant post-operative systemic inflammatory response (SIRS) [1]. The development of a subsequent post-surgical infection constitutes a common cause of morbidity and mortality, with intra-abdominal infections, in particular, resulting in high mortality rates due to the progression towards tertiary peritonitis and multiple organ dysfunction [2]. The relatively high incidence of infection development, coupled with the immense systemic inflammatory response generated following surgery, makes an early identification of infection problematic and may result in the suboptimal administration of antibiotics.
Current laboratory tools to aid infection diagnosis following surgery include the use of white cell counts (WCC), C-reactive protein (CRP), and procalcitonin (PCT). However, both WCC and CRP levels can be significantly increased in the absence of infection, whilst post-operative PCT concentrations may be heavily dependent on the type and complexity of the surgery performed [3]. Thus, complementary tools to aid diagnosis are required. Previous studies using mid-regional proadrenomedullin (MR-proADM) have highlighted its potential use as an early marker of sepsis development following severe burn injury [4] due to its involvement in the early stages of capillary leakage, endothelial dysfunction, and multiple organ failure [5, 6]. Accordingly, this biomarker may also be of interest following major surgery.
To test this hypothesis, all patients due to undergo cytoreductive surgery for peritoneal malignancy at the Basingstoke and North Hampshire Hospital were consecutively enrolled between January and December 2017. Kinetic profiles of MR-proADM and CT-proET-1 were compared with those of PCT, WCC, and CRP pre-, intra-, and post-operatively, and for 7 days following surgery.
A total of 50 patients were enrolled with an average operation duration of 7.1 (1.6) h (Table 1). All patients were treated with a combination of Metronidazole and Gentamicin during surgery, whilst 39 (78.0%) were administered vasopressors, 46 (92.0%) treated with intraperitoneal hyperthermic chemoperfusion (HIPEC), and 15 (30.0%) underwent a splenectomy. Furthermore, 15 (30.0%) patients required a blood transfusion during surgery, of which 10 (66.7%) required a follow-up transfusion 3.1 (2.3) days later. A clinical diagnosis of sepsis, defined by the presence of a clinical or radiological infectious focus, a positive pathogen identification and a SOFA score increase of ≥ 2 points, could be confirmed in 4 (8.0%) patients, with 6 (12.0%) additional patients satisfying the same criteria, albeit without a positive pathogen identification. The average time to infection diagnosis was 4.0 (2.1) days following surgery, with additional antibiotics initiated immediately upon diagnosis.
Table 1
Patient characteristics and subsequent operative requirements for patients prior to cytoreductive surgery within the total population and infected/non-infected subgroups
Patient characteristics
Total patient cohort (N = 50)
Non-infected patients (N = 40)
Infected patients (N = 10)
p value
Demographics
 Age (years) (mean, SD)
60.4 (13.1)
60.8 (12.7)
59.5 (15.9)
0.802
 Male gender (N, %)
24 (48.0%)
20 (50.0%)
4 (40.0%)
0.127
 BMI (kg/m2) (mean, SD)
28.5 (5.5)
28.4 (5.6)
29.0 (5.0)
0.763
Disposition
 Hospital duration (days) (median, Q1–Q3)
16.5 [13 – 20]
15.5 [12 – 19]
21 [17.25 – 22]
0.112
 ITU duration (days) (median, Q1–Q3)
2 [1.25 – 3]
2 [1 – 3]
2.5 [2 – 6]
0.288
Comorbidities
 Cardiovascular (N, %)
13 (26.0%)
11 (27.5%)
2 (20.0%)
0.873
 Respiratory (N, %)
3 (6.0%)
3 (7.5%)
0 (0.0%)
0.119
 Immunodeficiency (N, %)
0 (0.0%)
0 (0.0%)
0 (0.0%)
1.00
 Diabetes (N, %)
3 (6.0%)
3 (7.5%)
0 (0.0%)
0.117
 Renal (N, %)
0 (0.0%)
0 (0.0%)
0 (0.0%)
1.00
 Liver (N, %)
2 (8.0%)
2 (5.0%)
0 (0.0%)
0.274
 Central nervous system (N, %)
2 (8.0%)
2 (5.0%)
0 (0.0%)
0.288
Operative requirements
 Operation duration (h) (median, Q1–Q3)
7 [5.7 – 8.1]
6.7 [5.7 – 7.6]
8.7 [7.3 – 9.4]
0.035
 HIPEC (N, %)
46 (92.0%)
36 (90.0%)
10 (100.0%)
0.782
 Splenectomy (N, %)
15 (37.5%)
8 (20.0%)
7 (70.0%)
0.001
 Vasopressors (N, %)
39 (78.0%)
33 (82.5%)
6 (60.0%)
0.571
Biomarkers
 MR-proADM (nmol/L) (median, Q1–Q3)
0.59 [0.47 – 0.73]
0.61 [0.48 – 0.75]
0.56 [0.42 – 0.64]
0.983
 CT-proET-1 (pmol/L) (median, Q1–Q3)
63.1 [49.4 – 70.8]
63.9 [49.4 – 67.8]
62.2 [50.3 – 71.8]
0.984
 PCT (ng/mL) (median, Q1–Q3)
0.05 [0.03 – 0.07]
0.05 [0.03 – 0.07]
0.05 [0.03 – 0.09]
0.179
 CRP (mg/L) (median, Q1–Q3)
12 [7 – 18]
12 [7 – 22]
11 [6 – 18]
0.689
 WCC (109/L) (median, Q1–Q3)
8.0 [6.3 – 11.1]
7.9 [6.0 – 11.6]
8.0 [6.2 – 12.3]
0.816
Patients were classified into subgroups based on post-surgical infection development (infected vs. non-infected: N = 10 vs. N = 40; Table 1), with no differences in any biomarker concentration at pre-surgical or intra-surgical time points, or for CT-proET-1 in the subsequent days following surgery (Fig. 1). Significant differences, however, were found between both groups for MR-proADM, PCT, CRP, and WCC at varying time points. MR-proADM concentrations were significantly elevated 1 day (T + 1) after surgery and at all subsequent time points thereafter (infected vs. non-infected: 2.2 [1.5 – 2.5] vs. 1.2 [1.0 – 1.4] nmol/L; p < 0.001), whereas PCT concentrations were significantly elevated 2 days (T + 2) after surgery (infected vs. non-infected: 3.1 [1.4 – 4.5] vs. 0.7 [0.3 – 1.8] ng/mL; p < 0.01). Both CRP and WCC were only significantly elevated at time point T + 3 (p < 0.01). Corresponding AUROC analysis for MR-proADM at T + 1 was 0.90 [0.81 – 1.0] (cut-off: 1.96 nmol/L; sensitivity: 0.90 [0.60 – 0.98]; specificity: 0.85 [0.71 – 0.93]), whereas PCT at T + 2 was 0.77 [0.63 – 0.92] (cut-off: 0.68 ng/mL; sensitivity: 1.0 [0.72 – 1.0]; specificity: 0.48 [0.33 – 0.63]).
Results indicate that MR-proADM kinetics are increased earlier and are more accurate than PCT in identifying patients at risk of developing an infection after cytoreductive surgery for peritoneal malignancy. Additional studies with a larger sample size are required to confirm these hypothesis-generating findings.

Acknowledgements

We would like to thank Mr. Tom Cecil and his team in the Peritoneal Malignancy Unit, as well as the Pathology Governance Team and Biochemistry Departments at Hampshire Hospitals NHS Foundation Trust for their continuous support.
The study protocol was approved by the ethics board of the Hampshire Hospitals NHS Foundation Trust, and written informed consent obtained from all patients or their legal representatives where appropriate.
No individual participant data is reported that would require consent to publish from the participant (or legal parent or guardian for children).

Competing interests

All authors have provided information on potential conflicts of interests directly or indirectly related to the work submitted in the journal’s disclosure forms. All authors reported no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Saeed K, Dale AP, Leung E, Cusack T, Mohamed F, Lockyer G, et al. Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy. Eur J Surg Oncol. 2016;42(2):234–43.CrossRef Saeed K, Dale AP, Leung E, Cusack T, Mohamed F, Lockyer G, et al. Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy. Eur J Surg Oncol. 2016;42(2):234–43.CrossRef
2.
Zurück zum Zitat Evans HL, Raymond DP, Pelletier SJ, Crabtree TD, Pruett TL, Sawyer RG. Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care. 2001;7(2):117–21.CrossRef Evans HL, Raymond DP, Pelletier SJ, Crabtree TD, Pruett TL, Sawyer RG. Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care. 2001;7(2):117–21.CrossRef
3.
Zurück zum Zitat Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Post-operative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998;28:680–4.CrossRef Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Post-operative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998;28:680–4.CrossRef
4.
Zurück zum Zitat Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: a new biomarker for early diagnosis of sepsis in burned patients. J Burn Care Res. 2017;38:290–8.CrossRef Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: a new biomarker for early diagnosis of sepsis in burned patients. J Burn Care Res. 2017;38:290–8.CrossRef
5.
Zurück zum Zitat Elke G, Bloos F, Wilson DC, et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis--a secondary analysis of a large randomised controlled trial. Crit Care. 2018;22(1):79.CrossRef Elke G, Bloos F, Wilson DC, et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis--a secondary analysis of a large randomised controlled trial. Crit Care. 2018;22(1):79.CrossRef
6.
Zurück zum Zitat Elke G, Bloos F, Wilson DC, Meybohm P. Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores. Crit Care. 2018;22(1):147.CrossRef Elke G, Bloos F, Wilson DC, Meybohm P. Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores. Crit Care. 2018;22(1):147.CrossRef
Metadaten
Titel
Early sepsis identification following cytoreductive surgery for peritoneal malignancy
verfasst von
Darius Cameron Wilson
Danylo Yershov
Chandrakumaran Kandiah
Nicholas Cortes
Kirsty Gordon
Kordo Saeed
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 1/2020
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-2831-9

Weitere Artikel der Ausgabe 1/2020

Critical Care 1/2020 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.